Search for a clinical trial
Other search option(s)
17 Result(s)
Recruiting trial
= 
; Ongoing trial
= 
; Funded by an IRDiRC member = 
National clinical trial(s)
FRANCE
BRETAGNE
BREST
Thalidomide treatment for agnogenic myeloid metaplasia (Phase II) - Terminated -
CHU de Brest - Hôpital de la Cavale Blanche
Laboratoire d'hématologie
FRANCE
NORMANDIE
CAEN
A randomized study of thalidomide versus or with chemotherapy in a front-line therapy for de novo Multiple Myeloma (induction) and versus biphosphonates at plateau-phase (Phase III)
CHU de Caen - Hôpital de la Côte de Nacre
Institut d'Hématologie de Basse-Normandie
FRANCE
PAYS DE LA LOIRE
NANTES
A phase 3 study of Velcade (bortezomib) dexamethasone (VD) versus Velcade (bortezomib) thalidomide dexamethasone (VTD) as an induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma - FR
CHU de Nantes - Hôtel Dieu
Service d'hématologie clinique
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) as induction therapy and a randomized trial of Thalidomide vs Thalidomide plus oral Idarubicin as maintenance therapy in patients with Multiple Myeloma (Phase II) - DE
Institution: Information not provided - DE
ITALY
LOMBARDIA
PAVIA
Efficacy of Thalidomide in the Treatment of Severe Recurrent Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) (Phase II)- IT
Fondazione IRCCS Policlinico San Matteo
Clinica Medica III
ITALY
PIEMONTE
TORINO
A Phase II Multicenter Study of Melphalan, Prednisone, Thalidomide and Defibrotide in Advanced and refractory Multiple Myeloma Patients - IT
A.O.U. Città della Salute e della Scienza di Torino - Ospedale Molinette
S.C. di Ematologia
ITALY
PIEMONTE
TORINO
A multiarm, open label, randomized phase II study of MLN9708 plus oral dexamethasone or plus oral cyclophosphamide and dexamethasone or plus oral thalidomide and dexamethasone followed by maintenance with MLN9708 in newly diagnosed elderly multiple myeloma patients
Università degli Studi di Torino
Dipartimento di Biotecnologie Molecolari e Scienze per la Salute
ITALY
TRENTINO ALTO ADIGE
BOLZANO
Phase II Multicenter Clinical Trial to Investigate the Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib or Which Are Ineligible to One of These Drugs
Azienda Sanitaria dell'Alto Adige - Ospedale di Bolzano
Reparto di Ematologia e Centro Trapianto Midollo Osseo
NETHERLANDS
Utrecht
UTRECHT
Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma
UMC Utrecht - Universitair Medisch Centrum Utrecht
Afdeling Hematologie
SPAIN
Madrid
MADRID
A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With Melphalan/Prednisone/Velcade Versus Thalidomide / Prednisone / Velcade and Maintenance Treatment With Thalidomide / Velcade Versus Prednisone / Velcade in Untreated Patients With Multiple Myeloma More Than 65 Years Old (terminated)
Hospital Universitario 12 de Octubre
Servicio de Hematología y Hemoterapia
SPAIN
Madrid
MADRID
Phase 2a Single-Arm Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma (Completed)
Hospital Universitario 12 de Octubre
Servicio de Hematología y Hemoterapia
SPAIN
Madrid
MADRID
A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With Melphalan/Prednisone/Velcade Versus Thalidomide / Prednisone / Velcade and Maintenance Treatment With Thalidomide / Velcade Versus Prednisone / Velcade in Untreated Patients With Multiple Myeloma More Than 65 Years Old (terminated)
Hospital Universitario Ramón y Cajal
Servicio de Hematología y Hemoterapia
UNITED KINGDOM
Devon
EXETER
AITL: Phase II Trial of fludarabine and cyclophosphamide followed by Thalidomide for angioimmunoblastic lymphoma
Royal Devon and Exeter Hospital - Wonford site
Department of Haematology
UNITED KINGDOM
Greater London
LONDON
LLCG Study 12 : A Phase III Randomized, Double Blind, Placebo Controlled Trial Of Carboplatin/Etoposide With Or Without Thalidomide In Small Cell Lung Cancer
Middlesex Hospital
Meyerstein Institute of Oncology
UNITED KINGDOM
Greater Manchester
ADDRESS: NOT PROVIDED - UK
A Phase III, Randomized, Open-label, 3-arm Study to Determine the Efficacy and Safety of Lenalidomide (REVLIMID) Plus Low-dose Dexamethasone When Given Until Progressive Disease or for 18 Four-week Cycles Versus the Combination of Melphalan, Prednisone, and Thalidomide Given for 12 Six-week Cycles in Patients With Previously Untreated Multiple Myeloma...
Institution: Information not provided - UK
UNITED KINGDOM
Greater Manchester
ADDRESS: NOT PROVIDED - UK
The effect of Thalidomide on sputum biomarkers in IPF cough
Institution: Information not provided - UK
UNITED KINGDOM
West Midlands
BIRMINGHAM